World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
138
Citations
79574
World Ranking
1816
National Ranking
1036

Overview

William G. Wierda is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medicine, particularly in the areas of genetics, hematology, pathology and forensic medicine, oncology, and immunology.

The scientist's work covers a broad range of topics, with notable emphasis on chronic lymphocytic leukemia research, lymphoma diagnosis and treatment, chronic myeloid leukemia treatments, acute lymphoblastic leukemia research, CAR-T cell therapy research, acute myeloid leukemia research, and immunodeficiency and autoimmune disorders.

Frequent co-authors collaborating with William G. Wierda include:

  • Nitin Jain
  • Hagop M. Kantarjian
  • Alessandra Ferrajoli
  • Tapan M. Kadia
  • Elias Jabbour

The scientist publishes regularly in several venues, reflecting the focus on hematologic malignancies and related fields. Frequent publication venues include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • HemaSphere
  • Leukemia

Selected recent papers authored by or associated with William G. Wierda are:

  • Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors, 2020, New England Journal of Medicine
  • KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study, 2021, The Lancet
  • Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial, 2020, The Lancet
  • Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study, 2021, The Lancet
  • Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies, 2020, The Lancet

Best Publications

  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn

  • Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

    Andrew W. Roberts;Matthew S. Davids;John M. Pagel;Brad S. Kahl

  • Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

    Sattva S. Neelapu;Sudhakar Tummala;Partow Kebriaei;William Wierda

  • Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

    Enli Liu;David Marin;Pinaki Banerjee;Homer A. Macapinlac

  • Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

    Michael J. Keating;Susan O'Brien;Maher Albitar;Susan Lerner

  • Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Bonnie Harrington;Susan O'Brien;Jeffrey A. Jones

  • Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

    Hagop Kantarjian;Yasuhiro Oki;Guillermo Garcia-Manero;Xuelin Huang

  • Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

    Andrew W. Roberts;John F. Seymour;John F. Seymour;Jennifer R. Brown;William G. Wierda

  • Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

    Constantine S. Tam;Susan O'Brien;William Wierda;Hagop Kantarjian

  • Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

    Stephan Stilgenbauer;Barbara Eichhorst;Johannes Schetelig;Steven Coutre

  • Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Jan A. Burger

  • Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

    Enli Liu;Yijiu Tong;Gianpietro Dotti;Hila Shaim

  • Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

    William G. Wierda;Thomas J. Kipps;Jiří Mayer;Stephan Stilgenbauer

  • The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

    Sabine Ponader;Shih Shih Chen;Joseph J. Buggy;Kumudha Balakrishnan

  • Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

    Matthew S. Davids;Andrew W. Roberts;Andrew W. Roberts;John F. Seymour;John F. Seymour;John M. Pagel

  • Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia

    William Wierda;Susan O'Brien;Sijin Wen;Stefan Faderl

  • Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

    Susan O'Brien;Richard R Furman;Steven E Coutre;Jeff P Sharman

  • Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

    Deborah A. Thomas;Stefan Faderl;Susan O'Brien;Carlos Bueso-Ramos

  • The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

    Julia Hoellenriegel;Sarah A. Meadows;Mariela Sivina;William G. Wierda

  • Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

    Guillermo Garcia-Manero;Hagop M. Kantarjian;Blanca Sanchez-Gonzalez;Hui Yang

Frequent Co-Authors

Susan O'Brien
Susan O'Brien University of California, Irvine
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Alessandra Ferrajoli
Alessandra Ferrajoli The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
Jan A. Burger
Jan A. Burger The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Zeev Estrov
Zeev Estrov The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Nitin Jain
Nitin Jain The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in medical careers but not sure if a traditional MD program is right for you? There are several related degrees and alternative pathways in healthcare, many available online and designed to fit different academic backgrounds and career goals.

For those looking for a hands-on patient care role, some easiest nursing programs to get into offer flexible admission requirements and can be ideal for students seeking a direct path into nursing. There are also options like an lpn program without teas test, making it more accessible for prospective nurses to start their careers quickly.

If you are interested in the administrative or technical side of healthcare, consider exploring online medical billing and coding schools that accept fafsa. Programs like these can often be completed in less time and provide strong job prospects in the growing health information sector. Similarly, those with leadership aspirations may benefit from a health care administration degree online, which prepares graduates to manage teams, budgets, and strategic operations in clinics or hospitals.

These online programs offer flexibility and diverse entry points into the medical field, helping you find a rewarding career that fits your schedule and interests.

Best Scientists Citing William G. Wierda

Trending Scientists